5α-还原酶抑制剂与前列腺癌死亡率的关联
这项基于瑞典斯德哥尔摩的人群队列研究纳入349152名接受PSA检测的男性,评估5α-还原酶抑制剂(5-ARI)使用与前列腺癌死亡率(PCM)的关联。结果显示,5-ARI使用与PCM升高无关,且暴露时间越长PCM风险越低(>8年调整HR 0.44)。全因死亡率两组无显著差异。
要点
- 5-ARI使用与前列腺癌死亡率升高无关,长期使用(>8年)与PCM风险降低相关。
- 5-ARI组与未暴露组全因死亡率无统计学显著差异。
- 5-ARI组每年接受更多PSA检测和活检,原文指出需进一步研究差异源于药物效应还是检测差异。
核心结论
- 该队列研究结果提示,在无前列腺癌既往诊断的大规模人群队列中,5-ARI治疗与前列腺癌死亡率升高无关。
- 观察到时间依赖性关联,5-ARI治疗时间越长,PCM风险越低。
研究设计与样本
- 这是一项基于人群的队列研究,在瑞典斯德哥尔摩开展,研究时间为2007年1月1日至2018年12月31日。
- 共纳入429977名在研究期间接受PSA检测的男性,研究起点设为首次PSA检测后1年。
- 最终研究队列包括349152名男性;首次PSA检测后新配发2次及以上5-ARI(非那雄胺或度他雄胺)处方者定义为5-ARI使用者(n=26190)。
- 数据分析时间为2021年9月至2021年12月。
主要发现
- 5-ARI使用者(2次及以上处方)的中位年龄为66岁(IQR 61-73),未使用者为57岁(IQR 50-64)。
- 中位随访时间为8.2年(IQR 4.9-10),未暴露组共2257619人年,暴露组共124008人年。
- 5-ARI治疗的中位暴露时间为4.5年(IQR 2.1-7.4)。
- 随访期间共35767名男性(8.3%)死亡,其中852例死亡与前列腺癌相关。
- 调整多变量生存分析显示,5-ARI组暴露时间越长PCM风险越低:0.1-2.0年调整HR 0.89(95%CI 0.64-1.25);>8年调整HR 0.44(95%CI 0.27-0.74)。
局限性
- 原文指出需要进一步研究以确定观察到的差异是源于药物内在效应还是前列腺癌检测差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is evidence that 5α-reductase inhibitors (5-ARIs), a standard treatment of benign prostate hyperplasia, are associated with a decrease in the incidence of prostate cancer (PCa). However, studies to date have had conflicting results regarding the association with prostate cancer mortality (PCM). OBJECTIVE: To evaluate the association of treatment with 5-ARIs with PCM in men without a prior diagnosis of PCa. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study was conducted in Stockholm, Sweden, between January 1, 2007, and December 31, 2018, and included 429 977 men with a prostate-specific antigen (PSA) test within the study period. Study entry was set to 1 year after the first PSA test. Data were analyzed from September 2021 to December 2021. EXPOSURES: After their initial PSA test, men with 2 or more newly dispensed prescriptions of 5-ARI, finasteride, or dutasteride were considered 5-ARI users (n = 26 190). MAIN OUTCOMES AND MEASURES: Primary outcome was PCM. Cox proportional hazards regression models were used to calculate multivariable-adjusted hazard ratios (HRs) and 95% CIs for all-cause mortality and PCM. RESULTS: The study cohort included 349 152 men. The median (IQR) age for those with 2 or more filled prescriptions of 5-ARI was 66 (61-73) years and 57 (50-64) years for those without. The median follow-up time was 8.2 (IQR, 4.9-10) years with 2 257 619 person-years for the unexposed group and 124 008 person-years for the exposed group. The median exposure to treatment with 5-ARI was 4.5 (IQR, 2.1-7.4) years. During follow-up, 35 767 men (8.3%) died, with 852 deaths associated with PCa. The adjusted multivariable survival analysis showed a lower risk of PCM in the 5-ARI group with longer exposure times (0.1-2.0 years: adjusted HR, 0.89; 95% CI, 0.64-1.25; >8 years: adjusted HR, 0.44; 95% CI, 0.27-0.74). No statistically significant differences were seen in all-cause mortality between the exposed and unexposed group. Men treated with 5-ARIs underwent more PSA tests and biopsies per year than the unexposed group (median of 0.63 vs 0.33 and 0.22 vs 0.12, respectively). CONCLUSIONS AND RELEVANCE: The results of this cohort study suggest that there was no association between treatment with 5-ARI and increased PCM in a large population-based cohort of men without a previous PCa diagnosis. Additionally, a time-dependent association was seen with decreased risk of PCM with longer 5-ARI treatment. Further research is needed to determine whether the differences are because of intrinsic drug effects or PCa testing differences.
引用
- Björnebo L, Nordström T, Discacciati A, et al. Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality. JAMA Oncol. 2022. PMID: 35587340. doi:10.1001/jamaoncol.2022.1501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。